Form 8-K

8-K — Lifeward Ltd.

Accession: 0001178913-26-005208

Filed: 2026-11-13

Period: 2026-11-13

CIK: 0001607962

SIC: 3842 (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — zk2636410.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (exhibit_99-1.htm)

GRAPHIC (image_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: zk2636410.htm · Sequence: 1

false

0001607962

00-0000000

0001607962

2026-11-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND

EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

November 13, 2026

Lifeward

Ltd.

(Exact name of registrant as specified in its charter)

Israel

001-36612

Not applicable

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

2 Cabot Rd., Hudson, MA

01749

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: +508.251.1154

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to

Section 12(b) of the Exchange Act

Trading Symbol

Name of each exchange on which registered

Ordinary Shares, no par value

LFWD

Nasdaq Capital Market

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General

Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 13, 2026, Lifeward Ltd. (the “Company”)

issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of the press release is

being furnished herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1*

Press release dated November 13, 2026 of Lifeward Ltd., announcing financial results for the third quarter ended September 30, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Lifeward Ltd.

Dated: November 13, 2026

By:

/s/ Ronen Tsimerman

Name:

Ronen Tsimerman

Title:

Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: exhibit_99-1.htm · Sequence: 2

Exhibit 99.1

Lifeward

Reports Third Quarter 2026 Financial Results and Provides Business

Update

AlterG revenue increased 18% year-over-year

to $3.6 million, driven by higher U.S. unit shipments,

service revenue and average selling prices

The Company is advancing its transition

of ReWalk to a capital-efficient channel-partner distribution

model designed to expand patient access and support long-term revenue growth

New leadership team focused on commercial

execution and advancing AI-enabled rehabilitation

technologies

New peer-reviewed clinical evidence strengthens

support for ReWalk’s long-term benefits and

broader patient access

HUDSON, MA, and YOKNEAM ILLIT, Israel, November

13, 2026 – Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation

company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today reported financial results for

the third quarter ended September 30, 2026, and provided a business update.

Business Update

• Continued growth of AlterG. AlterG revenue increased 18% to $3.6 million in the third quarter of

2026 compared to the third quarter of 2025, primarily reflecting higher U.S. unit shipments, together with increased service revenue and

improved average selling prices. This marks the second consecutive quarter of double-digit year-over-year revenue growth for AlterG.

• ReWalk commercial transition to a channel-partner model. The Company is shifting ReWalk from

direct sales to partnerships with established home and durable medical equipment providers and patient care organizations that can

bring the ReWalk Personal Exoskeleton to patients across the United States. These partnerships build on the Company’s existing

channels, including CorLife, its exclusive distributor for patients with workers’ compensation claims, and the pilot program

the Company launched in August 2026 with Ottobock Care, a leading U.S. mobility technology patient care organization with more than

50 patient clinics nationwide. While the transition has affected the timing of ReWalk sales in the near term, the Company believes

channel partnerships have the potential to significantly increase ReWalk revenue over the long term and is focused on expanding its

partner network. Selling through partners on wholesale terms is also designed to reduce the Company’s operating expenses and

may accelerate cash collection compared with direct sales.

• Broad reimbursement access supporting ReWalk adoption. ReWalk is covered by Medicare for eligible

beneficiaries under an established fee schedule and by the three largest Medicare Advantage insurers, Aetna, Humana and UnitedHealthcare.

Medicare Fee-for-Service and many national Medicare Advantage plans are authorizing ReWalk for clinically appropriate patients, and the

Company believes this reimbursement infrastructure positions its channel partners to reach more eligible patients.

• Expansion of clinical evidence supporting ReWalk. In September and October 2026, the Company

announced the publication of two peer-reviewed real-world studies of the ReWalk Personal Exoskeleton. The first reported improved

performance of daily activities, higher satisfaction and lower pain compared with wheelchair use. The second, a long-term study,

reported sustained home use over a median of 33 months with no reported falls or exoskeleton-related fractures.

• Well positioned for artificial intelligence (“AI”)-enabled rehabilitation. As robotics

and AI increasingly move into physical care, the Company believes its combination of U.S. Food and Drug Administration (“FDA”)-cleared

robotic products, established reimbursement infrastructure, commercial channels and installed base position it to bring AI-enabled rehabilitation

technologies to patients. In addition to continued development of its upper-body exoskeleton with AI capabilities, Lifeward is exploring

the addition of other AI-enabled capabilities into its product development pipeline.

“The third quarter was a transitional

quarter for Lifeward, marked by continued AlterG growth as we move into the advanced stages of transitioning ReWalk to a channel-partner

distribution model,” said Josh Hexter, Interim Chief Executive Officer of Lifeward. “Moving away from direct sales can create

timing gaps in the near term, but we believe partnering with established providers that already reach patients nationwide is the right

path to significantly expand access to ReWalk and accelerate revenue growth over the long term.”

Third Quarter 2026 Financial Results

Revenue was $5.4 million in the third

quarter of 2026, compared to $6.2 million in the third quarter of 2025, a decrease of $0.8 million, or 12%. Revenue from AlterG products

and services increased 18% to $3.6 million, primarily reflecting higher U.S. unit shipments, together with increased service revenue and

improved average selling prices. Revenue from the sale of ReWalk Personal exoskeletons was $1.7 million, compared to $3.0 million in the

third quarter of 2025, reflecting lower U.S. sales as the Company transitions ReWalk to a channel-partner distribution model, as well

as lower revenues in Europe.

Gross margin was 27.4% during the

third quarter of 2026, compared to 43.7% in the third quarter of 2025. The year-over-year decrease was primarily attributable to adverse

foreign exchange rate fluctuations, higher freight costs and tariffs and revenue sharing expense arising from the Company’s March

2026 acquisition of Oratech Pharmaceuticals Ltd. from Oramed Pharmaceuticals Inc. (the “Oratech Acquisition”), under which

the Company agreed to make quarterly payments to Oramed based on sales of ReWalk Personal Exoskeleton products and related extended warranties.

On a non-GAAP basis, adjusted gross margin was 27.5% during the third quarter of 2026, compared to 43.7% in the prior-year quarter.

Total operating expenses in the third

quarter of 2026 were $7.5 million, compared to $5.9 million in the third quarter of 2025. The increase was primarily attributable to approximately

$0.5 million of clinical trial and contract research organization service costs related to the Oratech clinical trial, higher development

costs related to the AlterG product improvement project and the upper-body exoskeleton technology, higher spending on trade shows and

digital marketing, and restructuring expenses. On a non-GAAP basis, which excludes the items listed in the attached non-GAAP reconciliation

table, adjusted operating expenses were $7.0 million in the third quarter of 2026, compared to $5.7 million in the third quarter of 2025,

with the year-over-year change primarily attributable to the Oratech clinical trial costs and product development activities.

Operating loss in the third quarter

of 2026 was $6.0 million, compared to $3.1 million in the third quarter of 2025. On a non-GAAP basis, which excludes the items in the

attached non-GAAP reconciliation table, adjusted operating loss was $5.5 million in the third quarter of 2026, compared to $3.0 million

in the third quarter of 2025.

Net loss was $5.1 million, or $1.32

per share, in the third quarter of 2026, compared to $3.2 million, or $2.37 per share, in the third quarter of 2025. The increase primarily

reflects a higher operating loss partially offset by net financial income of $0.9 million in the third quarter of 2026, which includes

non-cash fair value changes in warrant and derivative liabilities as well as interest expense related to the Company’s convertible

notes. On a non-GAAP basis, which excludes the items in the attached non-GAAP reconciliation table, adjusted net loss was $5.5 million,

or $1.44 per share, in the third quarter of 2026, compared to $3.0 million, or $2.24 per share, in the third quarter of 2025.

Balance Sheet

Unrestricted cash and cash equivalents

were $4.5 million as of September 30, 2026, compared to $2.2 million as of December 31, 2025.

About Lifeward

Lifeward is a global innovator focused on

advancing medical technologies and biomedical solutions that improve lives. The Company’s established portfolio includes market-leading

neurorehabilitation technologies such as the ReWalk® Exoskeleton, AlterG® Anti-Gravity systems, and MyoCycle® FES System.

These solutions span the continuum of care in physical rehabilitation and recovery, deploying the most advanced robotics and AI technologies

to restore full health and quality of life to a broadening patient population. The Company is now executing a strategic evolution into

a diversified biomedical company, expanding beyond rehabilitation and into high-value therapeutic platforms. This includes its Protein

Oral Delivery (POD™) platform, designed to enable oral delivery of biologic drugs, with lead candidate ORMD-0801 (oral insulin)

targeting a large and underserved diabetes market.

Lifeward has operations in the United States,

Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com.

Lifeward®, ReWalk®, ReStore®

and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.

Use of Non-GAAP Financial Measures

In addition to financial results prepared in accordance with U.S.

GAAP, this earnings release includes certain non-GAAP financial measures, including adjusted gross profit, adjusted gross margin, adjusted

operating expenses, adjusted operating loss, adjusted net loss and adjusted net loss per share. These measures exclude certain items,

as applicable, including stock-based compensation expense, restructuring expense, acquired in-process research and development expense,

transaction-related expenses, amortization of acquired intangible assets, non-cash debt-discount amortization, changes in the fair value

of warrant and derivative liabilities, acquisition-related income or expense and other items reflected in the reconciliations below.

Management believes the non-GAAP financial

information provided in this release is useful to investors in understanding and assessing the Company’s ongoing operations. Management

uses both GAAP and non-GAAP information to evaluate and operate the business internally and believes it is useful to provide this information

to investors. Non-GAAP financial measures should not be considered in isolation or as a substitute for, or superior to, financial measures

prepared in accordance with U.S. GAAP. The GAAP results and reconciliations of the non-GAAP measures to the most directly comparable GAAP

measures are provided below.

Forward-Looking Statements

In addition to historical information, this

press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section

27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may

include projections regarding the Company’s future performance and other statements that are not statements of historical fact and,

in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,”

“could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,”

“predict,” “project,” “future,” “will,” “should,” “would,” “seek”

and similar terms or phrases. For example, when the Company discusses the transition of ReWalk to a channel-partner distribution model

and its potential to increase ReWalk revenue, the anticipated growth of AlterG, the development and potential benefits of AI-enabled capabilities

and products, reimbursement coverage, the expected benefits of the channel-partner model, including the potential for lower operating

expenses and faster cash collection, demand for rehabilitation technologies, and the Company’s strategy, priorities and long-term

growth, it is using forward-looking statements. The forward-looking statements contained in this press release are based on management’s

current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which

are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially

from those indicated in the forward-looking statements include, among others, risks and uncertainties relating to: the integration of

Oratech and realization of the anticipated benefits of the Oratech acquisition; the development, timing, results and regulatory approval

of ORMD-0801 and the Company’s other product and clinical-development programs; the sufficiency of the Company’s capital resources,

its ability to obtain additional financing and continue as a going concern, and potential dilution resulting from its outstanding convertible

securities and warrants; commercialization, market acceptance, reimbursement and sales growth for the Company’s products; the Company’s

reliance on third-party payors, manufacturers, suppliers and distributors, and its customer and trade-receivables concentration; recent

management and Board transitions; regulatory compliance, product defects and adverse events; intellectual-property protection; cybersecurity;

and legislative, regulatory, political and economic developments, as well as other factors discussed under the heading “Risk Factors”

in the Company’s annual report on Form 10-K, for the year ended December 31, 2025, in Part II, Item 1A of the Company’s Quarterly

Report on Form 10-Q for the quarter ended September 30, 2026, and in other documents

subsequently filed with, or furnished to, the SEC. Any forward-looking statement made in this press release speaks only as of the date

hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge

from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no

obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Contact

Ronen Tsimerman

Chief Financial Officer

Lifeward

E: media@golifeward.com

E: ir@golifeward.com

Lifeward Ltd. and subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

Three Months Ended

Nine Months Ended

September 30,

2026

2025

2026

2025

Revenue

$5,428

$6,195

$15,974

$16,953

Cost of revenues

3,941

3,488

10,436

9,613

Gross profit

1,487

2,707

5,538

7,340

Operating expenses:

Research and development, net

1,941

721

9,540

2,406

Sales and marketing

3,351

3,168

10,153

10,790

General and administrative

2,165

1,958

6,306

5,917

Impairment charges

2,783

Total operating expenses

7,457

5,847

25,999

21,896

Operating loss

(5,970 )

(3,140 )

(20,461 )

(14,556 )

Financial expense (income), net

(926)

6,879

(8 )

Loss before income taxes

(5,044 )

(3,163 )

(27,340 )

(14,548 )

Taxes on income

Net loss

$ (5,052 )

$ (3,170 )

$ (27,364 )

$ (14,566 )

Basic net loss per ordinary share

$ (1.32 )

$ (2.37 )

$ (9.91 )

$ (13.87 )

Weighted average number of shares used in computing net loss per ordinary share basic and diluted (*)

3,836,950

1,335,117

2,760,466

1,050,290

(*) All share and per share amounts presented in this note have

been retroactively adjusted to reflect the Company’s 1-for-12 reverse share split effected on February 24, 2026.

Lifeward Ltd. and subsidiaries

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

(Audited)

September 30,

December 31,

2026

2025

Assets

Current assets

Cash and cash equivalents

$4,548

$2,169

Restricted cash

240

Clinical trial services asset

539

Trade receivables, net of credit losses of $209 and $192, respectively

7,649

6,138

Prepaid expenses and other current assets

2,261

1,528

Inventories

6,697

5,732

Total current assets

21,697

15,807

Restricted cash and other long term assets

484

209

Clinical trial services asset

269

Operating lease right-of-use assets

2,441

1,544

Property and equipment, net

463

585

Intangible assets

409

Goodwill

4,755

Total assets

$ 30,518

$22,900

Liabilities and equity

Current liabilities

Trade payables

$5,838

$5,590

Current maturities of operating leases

762

425

Convertible promissory note

2,803

Other current liabilities

4,255

3,221

Total current liabilities

10,855

12,039

Non-current operating leases

1,712

1,159

Convertible promissory notes, net

7,133

Warrants liability

1,988

Other long-term liabilities

1,563

1,294

Shareholders’ equity

7,267

8,408

Total liabilities and equity

$ 30,518

$22,900

Lifeward Ltd. and subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

Nine Months Ended

September 30,

2026

2025

Net cash used in operating activities

$ (16,064 )

$ (13,271 )

Net cash used in investing activities

(28 )

(5 )

Net cash provided by financing activities

18,502

8,425

Effect of exchange rate changes on cash, cash equivalents and restricted cash

(9 )

103

Increase (decrease) in cash, cash equivalents, and restricted cash

2,401

(4,748 )

Cash, cash equivalents, and restricted cash at beginning of period

2,579

7,108

Cash, cash equivalents, and restricted cash at end of period

$4,980

$2,360

Lifeward Ltd. and subsidiaries

(Unaudited)

(In thousand)

Three Months Ended

Nine Months Ended

September 30,

2026

2025

2026

2025

Revenues based on customer’s location:

United States

$3,270

$4,044

$9,692

$10,263

Europe

613

627

2,370

2,100

Germany

1,003

1,192

2,835

3,209

Asia-Pacific

298

103

586

269

Rest of the world

244

229

491

1,112

Total revenues

$5,428

$6,195

$15,974

$16,953

Lifeward Ltd. and subsidiaries

Reconciliation of GAAP to Non-GAAP Financial

Measures

(Unaudited)

(In thousands)

Three Months Ended

Nine Months Ended

September 30,

Dollars in thousands, except per share data

2026

2025

2026

2025

GAAP net loss

$ (5,052 )

$ (3,170 )

$ (27,364 )

$ (14,566 )

Adjustments:

Amortization of intangible assets

Non-cash acquired in-process R&D expense

4,947

Oramed transaction-related expenses

619

Other income related to the settlement of the post closing statement for the acquisition of AlterG

(142 )

Restructuring

300

544

700

Remeasurement of earnout liability

(608 )

Impairment charges

2,783

Stock-based compensation expenses

103

174

542

576

Non-cash amortization of debt discount associated with the convertible notes and warrants

457

1,415

Fair value remeasurement of warrant and derivative liabilities

(1,347)

5,041

Non-GAAP net loss

$ (5,516 )

$ (2,996 )

$ (14,365 )

$ (11,115 )

Weighted average shares used in computing net loss per share (*)

3,836,950

1,335,117

2,760,466

1,050,290

Non-GAAP net loss per share

$ (1.44 )

$ (2.24 )

$ (5.20 )

$ (10.58 )

(*) All share and per share amounts presented in this note have

been retroactively adjusted to reflect the Company’s 1-for-12 reverse share split effected on February 24, 2026.

Lifeward Ltd. and subsidiaries

Reconciliation of GAAP to Non-GAAP Financial

Measures

(Unaudited)

(In thousands)

Three Months Ended September 30,

Nine Months Ended September 30,

2026

2025

2026

2025

Dollars in thousands

% of revenue

GAAP operating loss

$ (5,970 )

(110.0 )%

$ (3,140 )

(50.7 )%

$ (20,461 )

(128.1 )%

$ (14,556 )

(85.9 )%

Amortization of intangible assets

0.4%

0.2%

Non-cash acquired in-process R&D expense

4,947

31.0%

Oramed transaction-related expenses

619

3.9%

Other income related to the settlement of the post closing statement for the acquisition of AlterG

(142 )

(0.9 )%

Restructuring

300

5.5%

544

3.4%

700

4.1%

Remeasurement of earnout liability

(608 )

(3.6 )%

Impairment charges

2,783

16.4%

Stock-based compensation expenses

103

1.9%

174

2.8 %

542

3.4%

576

3.4%

Non-GAAP operating loss

$ (5,544 )

(102.2 )%

$ (2,966 )

(47.9 )%

$ (13,918 )

(87.1 )%

$ (11,105 )

(65.6 )%

Three Months Ended September 30,

Nine Months Ended September 30,

2026

2025

2026

2025

Dollars in thousands

% of revenue

GAAP gross profit

$ 1,487

27.4 %

$ 2,707

43.7 %

$5,538

34.7 %

$ 7,340

43.3 %

Adjustments:

Stock-based compensation expenses

0.1 %

0.0 %

0.1 %

Non-GAAP gross profit

$ 1,491

27.5 %

$ 2,710

43.7 %

$ 5,548

34.8 %

$ 7,350

43.4 %

Three Months Ended September 30,

Nine Months Ended September 30,

2026

2025

2026

2025

Dollars in thousands

% of revenue

GAAP research & development

1,941

35.8 %

721

11.6 %

9,540

59.7 %

$2,406

14.2 %

Adjustments:

Amortization of intangible assets

(23 )

(0.4 )%

(33 )

(0.2 )%

Non-cash acquired in-process R&D expense

(4,947 )

(31.0 )%

Stock-based compensation expenses

(30 )

(0.6 )%

(32 )

(0.5 )%

(104 )

(0.7 )%

(105 )

(0.6 )%

Non-GAAP research & development

$1,888

34.8%

$689

11.1%

$4,456

27.8%

$2,301

13.6%

Lifeward Ltd. and subsidiaries

Reconciliation of GAAP to Non-GAAP Financial

Measures

(Unaudited)

(In thousands)

Three Months Ended September 30,

Nine Months Ended September 30,

2026

2025

2026

2025

Dollars in thousands

% of revenue

GAAP sales & marketing

$3,351

61.7 %

3,168

51.1 %

10,153

63.6 %

10,790

63.6 %

Adjustments:

Restructuring

(244 )

(1.5 )%

(277 )

(1.6 )%

Stock-based compensation expenses

(36 )

(0.7 )%

(65 )

(1.0 )%

(99 )

(0.6 )%

(203 )

(1.2 )%

Non-GAAP sales & marketing

$3,315

61.0%

$3,103

50.1%

$9,810

61.5%

$10,310

60.8%

Three Months Ended September 30,

Nine Months Ended September 30,

2026

2025

2026

2025

Dollars in thousands

% of revenue

GAAP general & administrative

2,165

39.9 %

1,958

31.6 %

6,306

39.5 %

5,917

34.9 %

Adjustments:

Other income related to the settlement of the post closing statement for the acquisition of AlterG

142

0.9%

Oramed transaction-related expenses

(619 )

(3.9 )%

Restructuring

(300 )

(5.5 )%

(300 )

(1.9 )%

(423 )

(2.5 )%

Remeasurement of earnout liability

608

3.6%

Stock-based compensation expenses

(33 )

(0.6 )%

(74 )

(1.2 )%

(329 )

(2.1 )%

(258 )

(1.5 )%

Non-GAAP general & administrative

$1,832

33.8%

$1,884

30.4%

$5,200

32.5%

$5,844

34.5%

GRAPHIC

Filename: image_001.jpg · Sequence: 6

Binary file (2956 bytes)

Download image_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Nov. 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Nov. 13, 2026

Entity File Number

001-36612

Entity Registrant Name

Lifeward

Ltd.

Entity Central Index Key

0001607962

Entity Tax Identification Number

00-0000000

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2 Cabot Rd.

Entity Address, City or Town

Hudson

Entity Address, State or Province

Entity Address, Postal Zip Code

01749

City Area Code

+508

Local Phone Number

251.1154

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Ordinary Shares, no par value

Trading Symbol

LFWD

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Entity Information, Former Legal or Registered Name

Not Applicable

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Former Legal or Registered Name of an entity

+ References

No definition available.

+ Details

Name:

dei_EntityInformationFormerLegalOrRegisteredName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration